Penny Stock, Fireman's Contractors (OTCBB: FRCN) Founded by Fireman, Gives Back To Firefighters
POINT ROBERTS - October 6, 2011 - www.InvestorIdeas.com, a leader in sector stock research including construction stocks, homebuilder and infrastructure stocks issues a company profile and investor alert for recently listed Fireman's Contractors Inc. (OTCBB: FRCN).
The Company was founded by fireman, Aaron Gilmore, Chief Operations Officer. Mr. Gilmore also currently serves as a firefighter for Hurst Fire Department, located in Hurst, Texas, a position he has held since April 2002.
Fireman's Contractors Inc. (OTCBB: FRCN) is a full service contractor providing superior service in parking lot maintenance and construction services. Services include Road Improvements, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, ADA Compliance and other construction services which are delivered at a competitive price. Fireman's brings professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations.
The idea of donating proceeds back to fireman is not new, and has a long lasting legacy with Fireman's Fund Insurance Company.
Fireman's Fund Insurance Company, a division of Allianz Group (ALV.DE) name reflects its founding mission in which 10 percent of the profits were paid to the widows and orphans of fallen firefighters.
Founded in 1863, Fireman's Fund Insurance Company is a premier property and casualty insurance company providing personal and commercial insurance products backed by industry-leading claims and risk management solutions. Fireman's Fund is a leader in high-net-worth, entertainment, and green insurance. Fireman's Fund is a member of the Allianz Group, one of the world's largest providers of property and casualty insurance, ranked 27th on Fortune's Global 500 list of the world's largest corporations. www.firemansfund.com.
Showcase Infrastructure Stock Fireman's Contractors Inc. (OTCBB: FRCN)
Visit the company Profile on Investorideas.com
http://www.investorideas.com/CO/FRCN/
Company website: http://www.firemans-contractors.com/
Follow FIREMANS CONTRACTORS, Inc. (OTCBB: FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB: FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors
IR Contact info:
Tel: 1(214) 314-1588
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: Fireman's Contractors Inc. (OTCBB: FRCN) is a paid adverting construction stock on Investorideas.com and blogs (ten thousand for 3 months of advertising)
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411
Thursday, October 06, 2011
Morning Penny Stock Volume Leaders on OTC: (OTC: AFPW), (OTC: AAVG), (OTC: NXOI), (OTC: GERS)
POINT ROBERTS - October 6, 2011 - www.InvestorIdeas.com, a globalinvestor
research portal for independent investors, reports on top volume traders on the OTC for Thursday morning trading. The top four traders includes two green/renewable energy stocks .
AlumiFuel Power Corp. (OTC: AFPW ) The stocks is trading at $ 0.002, up 0.0005 (+33.33%) on volume of 32.96 M. The company reported the following news this morning “Early production stage hydrogen generation company AlumiFuel Power, Inc. ("API"), the Philadelphia, Pennsylvania-based wholly owned operating subsidiary of AlumiFuel Power Corporation (OTCBB: AFPW) (the "Company"), announced today it has been awarded a contract to deliver a PBIS-2000 Portable Balloon Inflation System to the Air Force Special Operations Command (AFSOC). The Company believes that this initial purchase will lead to additional units for operations throughout the world. In addition, the Company has been approached by other military and meteorological users from the US, NATO, and around the world interested in the Portable Balloon Inflation System technology and products."
AvStar Aviation Group Inc.(OTC: AAVG ) is trading at 0,0027 ,up 8,00 % on 11,89 M shares .
Next 1 Interactive Inc.(OTC:NXOI) reported news that Next 1 in combination with its partner RealBiz Media, completed a flawless testing period of its "Home Tour Network" Video On Demand (VOD) platform in Los Angeles and Washington, D.C. The technical test launch passed with flying colors, resulting in 100% of the submitted local home listing videos and advertisements playing error free, on the Cable TV platform. The stock is trading at 0.025, up 0.013 108.33% on 6.89 M shares.
Greenshift Corp. (OTC: GERS ) is trading flat on over 5 M shares. The last news from the Company, September 20 th, was that it had filed motions to amend its complaints against all defendants, including Colwich, Kansas-based ICM, Inc., in GreenShift’s ongoing litigation for infringement of GreenShift’s patented corn oil extraction processes.
Investorideas.com Free Investor Tools;
Learn More about Investorideas.com showcase stocks
http://www.investorideas.com/Showcase/
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Become a Member
Research renewable energy stocks, gold stocks, water stocks, oil and gas and more with the largest stock directories online for investors
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including renewableenergy , water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411
POINT ROBERTS - October 6, 2011 - www.InvestorIdeas.com, a global
AlumiFuel Power Corp. (OTC: AFPW ) The stocks is trading at $ 0.002, up 0.0005 (+33.33%) on volume of 32.96 M. The company reported the following news this morning “Early production stage hydrogen generation company AlumiFuel Power, Inc. ("API"), the Philadelphia, Pennsylvania-based wholly owned operating subsidiary of AlumiFuel Power Corporation (OTCBB: AFPW) (the "Company"), announced today it has been awarded a contract to deliver a PBIS-2000 Portable Balloon Inflation System to the Air Force Special Operations Command (AFSOC). The Company believes that this initial purchase will lead to additional units for operations throughout the world. In addition, the Company has been approached by other military and meteorological users from the US, NATO, and around the world interested in the Portable Balloon Inflation System technology and products."
AvStar Aviation Group Inc.(OTC: AAVG ) is trading at 0,0027 ,up 8,00 % on 11,89 M shares .
Next 1 Interactive Inc.(OTC:NXOI) reported news that Next 1 in combination with its partner RealBiz Media, completed a flawless testing period of its "Home Tour Network" Video On Demand (VOD) platform in Los Angeles and Washington, D.C. The technical test launch passed with flying colors, resulting in 100% of the submitted local home listing videos and advertisements playing error free, on the Cable TV platform. The stock is trading at 0.025, up 0.013 108.33% on 6.89 M shares.
Greenshift Corp. (OTC: GERS ) is trading flat on over 5 M shares. The last news from the Company, September 20 th, was that it had filed motions to amend its complaints against all defendants, including Colwich, Kansas-based ICM, Inc., in GreenShift’s ongoing litigation for infringement of GreenShift’s patented corn oil extraction processes.
Investorideas.com Free Investor Tools;
Learn More about Investorideas.com showcase stocks
http://www.investorideas.com/Showcase/
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Become a Member
Research renewable energy stocks, gold stocks, water stocks, oil and gas and more with the largest stock directories online for investors
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including renewable
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411
Red Fork Energy Limited (ASX: RFE) News; Wire-line Log Results Confirm Very Large Reservoir Tahara #1-28H Well, Pawnee County, Oklahoma
October 6, 2011 (Investorideas.com Newswire) Oklahoma based (Australian Securities Exchange listed) oil and gas exploration and production company, Red Fork Energy Limited (ASX: RFE) ("Red Fork" or the "Company") is pleased to provide the following summary of the results of the comprehensive wire-line logging operations conducted on its first long lateral in the Mississippi Lime formation in Pawnee County, Oklahoma.
The Company engaged Schlumberger to run and analyze a full suite of open hole logs, including Triple Combo (with ELAN analysis), FMI and Sonic logs of the full length of the lateral in the recently drilled, cased and cemented Tahara #1-28H well.
Based on the analysis of data from these logging operations Schlumberger have provided estimates of OOIP place, identifying 58.4mmbo per square mile (640 acre section) or 109.26 barrels of oil per acre foot.
The Company expects that this OOIP result will deliver a very large increase in recoverable reserves per square mile (640 acres section). Using a conservative recovery factor the recoverable reserves per section could be as much as three times the current reported industry average. In addition to the OOIP, the Company expects to recover additional associated (high BTU) gas based on a factor of between 3mcf and 5mcf per barrel
Importantly, analysis of the logs identified approximately 835 feet of oil filled fractures encountered in interbedded Mississippi Limestone and chert throughout the length of the lateral. The lateral was generally positioned in the center of the Mississippi Limestone formation in an area of interbedded limestone and chert intervals, with cuttings typically showing a percentage of both limestone and chert.
Work to finalize the perforation and reservoir stimulation plan is now underway and data from this comprehensive logging operation will be incorporated in the final design of the completion plan as the well is prepared for production. Gas and water lines are being extended to existing sales and disposal infrastructure to service this well and the Abunda #1-21H well that is currently being drilled from this twin well location.
Commenting on this release, Red Fork Managing Director, David Prentice, said, "We are very pleased that this analysis of data from our first long lateral in the Mississippi in Pawnee County has delivered these very significant estimates of oil in place."
"This is a strong endorsement of the methodologies we used in the selection of our acreage in this exciting play in Oklahoma and we are looking forward to continuing our efforts in securing additional infill select high-grade acres in the play and progressing our 2011 horizontal drilling program."
Yours faithfully
David Prentice
Managing Director
Forward Looking Statements
This announcement contains "forward-looking statements". Such forward-looking statements include, without limitation: estimates of future earnings, the sensitivity of earnings to oil & gas prices and foreign exchange rate movements; estimates of future oil & gas production and sales; estimates of future cash flows, the sensitivity of cash flows to oil & gas prices and foreign exchange rate movements; statements regarding future debt repayments; estimates of future capital expenditures; estimates of reserves and statements regarding future exploration results and the replacement of reserves; and where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. However, forward looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such risks include, but are not limited to oil and gas price volatility, currency fluctuations, increased production costs and variances in reserves or recovery rates from those assumed in the company�s plans, as well as political and operational risks in the countries and states in which we operate or sell product to, and governmental regulation and judicial outcomes. For a more detailed discussion of such risks and other factors, see the Company�s Annual Reports, as well as the Company�s other filings. The Company does not undertake any obligation to release publicly any revisions to any "forward looking statement" to reflect events or circumstances after the date of this release, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
October 6, 2011 (Investorideas.com Newswire) Oklahoma based (Australian Securities Exchange listed) oil and gas exploration and production company, Red Fork Energy Limited (ASX: RFE) ("Red Fork" or the "Company") is pleased to provide the following summary of the results of the comprehensive wire-line logging operations conducted on its first long lateral in the Mississippi Lime formation in Pawnee County, Oklahoma.
The Company engaged Schlumberger to run and analyze a full suite of open hole logs, including Triple Combo (with ELAN analysis), FMI and Sonic logs of the full length of the lateral in the recently drilled, cased and cemented Tahara #1-28H well.
Based on the analysis of data from these logging operations Schlumberger have provided estimates of OOIP place, identifying 58.4mmbo per square mile (640 acre section) or 109.26 barrels of oil per acre foot.
The Company expects that this OOIP result will deliver a very large increase in recoverable reserves per square mile (640 acres section). Using a conservative recovery factor the recoverable reserves per section could be as much as three times the current reported industry average. In addition to the OOIP, the Company expects to recover additional associated (high BTU) gas based on a factor of between 3mcf and 5mcf per barrel
Importantly, analysis of the logs identified approximately 835 feet of oil filled fractures encountered in interbedded Mississippi Limestone and chert throughout the length of the lateral. The lateral was generally positioned in the center of the Mississippi Limestone formation in an area of interbedded limestone and chert intervals, with cuttings typically showing a percentage of both limestone and chert.
Work to finalize the perforation and reservoir stimulation plan is now underway and data from this comprehensive logging operation will be incorporated in the final design of the completion plan as the well is prepared for production. Gas and water lines are being extended to existing sales and disposal infrastructure to service this well and the Abunda #1-21H well that is currently being drilled from this twin well location.
Commenting on this release, Red Fork Managing Director, David Prentice, said, "We are very pleased that this analysis of data from our first long lateral in the Mississippi in Pawnee County has delivered these very significant estimates of oil in place."
"This is a strong endorsement of the methodologies we used in the selection of our acreage in this exciting play in Oklahoma and we are looking forward to continuing our efforts in securing additional infill select high-grade acres in the play and progressing our 2011 horizontal drilling program."
Yours faithfully
David Prentice
Managing Director
Forward Looking Statements
This announcement contains "forward-looking statements". Such forward-looking statements include, without limitation: estimates of future earnings, the sensitivity of earnings to oil & gas prices and foreign exchange rate movements; estimates of future oil & gas production and sales; estimates of future cash flows, the sensitivity of cash flows to oil & gas prices and foreign exchange rate movements; statements regarding future debt repayments; estimates of future capital expenditures; estimates of reserves and statements regarding future exploration results and the replacement of reserves; and where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. However, forward looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such risks include, but are not limited to oil and gas price volatility, currency fluctuations, increased production costs and variances in reserves or recovery rates from those assumed in the company�s plans, as well as political and operational risks in the countries and states in which we operate or sell product to, and governmental regulation and judicial outcomes. For a more detailed discussion of such risks and other factors, see the Company�s Annual Reports, as well as the Company�s other filings. The Company does not undertake any obligation to release publicly any revisions to any "forward looking statement" to reflect events or circumstances after the date of this release, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
Red Fork Energy Limited (ASX: RFE) is a showcase energy stock on Investorideas.com
Visit the Red Fork Energy Limited (ASX: RFE) profile page
Disclosure/Disclaimer: Red Fork Energy Limited (ASX: RFE) June 8 2011 - one month on Investorideas.com and energy blogs June 8 2011 (on thousand)
Visit the Red Fork Energy Limited (ASX: RFE) profile page
Disclosure/Disclaimer: Red Fork Energy Limited (ASX: RFE) June 8 2011 - one month on Investorideas.com and energy blogs June 8 2011 (on thousand)
Wednesday, October 05, 2011
City Windmills Ltd. (CYW.F) (CYW.DE) Attends the European Future Energy Forum
MANCHESTER, U.K. - October 5, 2011 (Investorideas.com renewable energy/green newswire) - City Windmills, Ltd. (Frankfurt symbol: CYW, CYW.DE) - www.citywindmills.com), announces its participation in the European Future Energy Forum from October 10 through 12, 2011 in Geneva, Switzerland at the Palexpo convention center.
The European Future Energy Forum (EFEF - http://www.europeanfutureenergyforum.com) is an initiative developed with Masdar - Abu Dhabi�s multi-faceted, multi-billion dollar investment in the development and commercialization of innovative technologies in renewable, alternative and sustainable energies. EFEF was launched in 2009 following the success of the World Future Energy Summit held annually in Abu Dhabi. Now established as an annual event in its own right, this will be the 3rd European Future Energy Forum following high-quality forums in Bilbao and London. The Conference will host several key players in the green energy production arena, such as Vestas, ABB, Masdar, Oerlikon Solar and City Windmills.
Roland Bopp, CEO of City Windmills Ltd. said, "With our participation at the European Future Energy Forum, we have the opportunity to showcase the company's solutions to corporations, corporate buildings and our unique flat panel advertising capabilities. I am honored the EFEF has asked me to speak on the Wind Panel on Wednesday October 12, 2011 from 09:30 to 11:00am. We expect our windmill system to be showcased to 150 journalists and 4�000 green energy professionals over the three full days at this event."
City Windmills Ltd. is a windmill company seeking to transform the dominant paradigm of energy production and consumption around the globe, by integrating the three notions of powerful energy production from wind, proximity to the end user and advertisement of brands and products.
This press release may contain 'forward-looking statements.' Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan.
CONTACT:
Peter Kazimirski, CEO, +41 79 663 5234, peter.kazimirski@citywindmills.com
Sean Kelly, CFO, +41 79 203 7124, sean.kelly@citywindmills.com
MANCHESTER, U.K. - October 5, 2011 (Investorideas.com renewable energy/green newswire) - City Windmills, Ltd. (Frankfurt symbol: CYW, CYW.DE) - www.citywindmills.com), announces its participation in the European Future Energy Forum from October 10 through 12, 2011 in Geneva, Switzerland at the Palexpo convention center.
The European Future Energy Forum (EFEF - http://www.europeanfutureenergyforum.com) is an initiative developed with Masdar - Abu Dhabi�s multi-faceted, multi-billion dollar investment in the development and commercialization of innovative technologies in renewable, alternative and sustainable energies. EFEF was launched in 2009 following the success of the World Future Energy Summit held annually in Abu Dhabi. Now established as an annual event in its own right, this will be the 3rd European Future Energy Forum following high-quality forums in Bilbao and London. The Conference will host several key players in the green energy production arena, such as Vestas, ABB, Masdar, Oerlikon Solar and City Windmills.
Roland Bopp, CEO of City Windmills Ltd. said, "With our participation at the European Future Energy Forum, we have the opportunity to showcase the company's solutions to corporations, corporate buildings and our unique flat panel advertising capabilities. I am honored the EFEF has asked me to speak on the Wind Panel on Wednesday October 12, 2011 from 09:30 to 11:00am. We expect our windmill system to be showcased to 150 journalists and 4�000 green energy professionals over the three full days at this event."
City Windmills Ltd. is a windmill company seeking to transform the dominant paradigm of energy production and consumption around the globe, by integrating the three notions of powerful energy production from wind, proximity to the end user and advertisement of brands and products.
This press release may contain 'forward-looking statements.' Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan.
CONTACT:
Peter Kazimirski, CEO, +41 79 663 5234, peter.kazimirski@citywindmills.com
Sean Kelly, CFO, +41 79 203 7124, sean.kelly@citywindmills.com
City Wind Mills, Ltd.. (CYW.F) is a Frankfurt listed wind stock showcased on Investorideas.com and related green blogs
Visit the showcase profile for City Wind Mills, Ltd.. (CYW.F) to learn more
Request new, articles and trading alerts on City Wind Mills, Ltd.. (CYW.F)
Disclosure: City Wind Mills, Ltd. (CYW.F) is a paid advertising online client ( 6 months � thirty five hundred per month , five thousand shares)
Visit the showcase profile for City Wind Mills, Ltd.. (CYW.F) to learn more
Request new, articles and trading alerts on City Wind Mills, Ltd.. (CYW.F)
Disclosure: City Wind Mills, Ltd. (CYW.F) is a paid advertising online client ( 6 months � thirty five hundred per month , five thousand shares)
Gold Stocks News; Lomiko (TSX-V: LMR; OTC: LMRMF) Discovers Significant Gold, Silver and Zinc Soil Anomalies at Vines Lake Property; Drill Results Pending
Vancouver, BC - October 5, 2011 (Investorideas.com mining stocks newswire) � LOMIKO METALS INC. (TSX-V:LMR, OTC: LMRMF, Europe: ISIN: CA54163Q1028, WKN: A0Q9W7) (the "Company") is pleased to announce a new discovery of Zinc during the 2011 soil geochemistry survey. The anomalous zone covers a large 108 Hectare area in the southwestern corner of Lomiko's 2011 claim block in the Cassiar District or 'Cassiar Camp'. Rock samples and drill results are pending.
A geochemical soil survey and geological mapping survey was completed over the initial Lomiko Metals' claim block covering a total area of 1,209 Ha. The Vines Lake Property has since been increased to 5,403 Ha. The survey grid covered 75 line kilometers. Soil samples were taken at 50 meter intervals on north-south orientated lines spaced 200 meters apart. Claim boundaries were also sampled.
A total of 1,366 B-horizon soil samples and 74 rock samples were collected and sent in for multi-element ICP analysis to the Stewart Group - Eco Tech Laboratory in Kamloops BC which is now owned by the ALS Minerals based out of Vancouver, BC.
Soil analyses results have outlined numerous anomalous gold values up to 0.279 g/t mostly on the eastern side of the property adjacent to China Minerals Mining's Table Mountain Gold property. Silver anomalies, also seen on the eastern portion of the property and not always coincident with gold anomalies included results up to 19.50 g/t.
Numerous Barium and Bismuth anomalies are outlined, with results returning values up to 1413 ppm and 3.48 ppm respectively.
Zinc values in soil, on the western side of Vines Lake were by far the most anomalous on the property with values reported up to 2,429 ppm. One anomalous zone on the west side of the property measures 108 Ha with an average Zn value of 430 ppm.
The company focused efforts on a large data collection program that would identify new high-grade gold vein systems and other intrusion related mineralization in proximity to the Cassiar Batholith and its associated boundary contacts, over which Lomiko's Vines Lake property claims are located.
Cassiar Area Highlights:
On behalf of Lomiko Metals Inc,
A. Paul Gill, President & CEO
We seek safe harbor.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
647-607-6023
Bay Street Connect
info@lomiko.com
Lomiko Metals Inc.
www.lomiko.com
Vancouver, BC - October 5, 2011 (Investorideas.com mining stocks newswire) � LOMIKO METALS INC. (TSX-V:LMR, OTC: LMRMF, Europe: ISIN: CA54163Q1028, WKN: A0Q9W7) (the "Company") is pleased to announce a new discovery of Zinc during the 2011 soil geochemistry survey. The anomalous zone covers a large 108 Hectare area in the southwestern corner of Lomiko's 2011 claim block in the Cassiar District or 'Cassiar Camp'. Rock samples and drill results are pending.
A geochemical soil survey and geological mapping survey was completed over the initial Lomiko Metals' claim block covering a total area of 1,209 Ha. The Vines Lake Property has since been increased to 5,403 Ha. The survey grid covered 75 line kilometers. Soil samples were taken at 50 meter intervals on north-south orientated lines spaced 200 meters apart. Claim boundaries were also sampled.
A total of 1,366 B-horizon soil samples and 74 rock samples were collected and sent in for multi-element ICP analysis to the Stewart Group - Eco Tech Laboratory in Kamloops BC which is now owned by the ALS Minerals based out of Vancouver, BC.
Soil analyses results have outlined numerous anomalous gold values up to 0.279 g/t mostly on the eastern side of the property adjacent to China Minerals Mining's Table Mountain Gold property. Silver anomalies, also seen on the eastern portion of the property and not always coincident with gold anomalies included results up to 19.50 g/t.
Numerous Barium and Bismuth anomalies are outlined, with results returning values up to 1413 ppm and 3.48 ppm respectively.
Zinc values in soil, on the western side of Vines Lake were by far the most anomalous on the property with values reported up to 2,429 ppm. One anomalous zone on the west side of the property measures 108 Ha with an average Zn value of 430 ppm.
The company focused efforts on a large data collection program that would identify new high-grade gold vein systems and other intrusion related mineralization in proximity to the Cassiar Batholith and its associated boundary contacts, over which Lomiko's Vines Lake property claims are located.
Cassiar Area Highlights:
- A new company with Chinese investors known as China Minerals Mining Corporation is located adjacent to the property.
- A fully permitted 270 tonne per day, gravity and flotation mill, power plant, assay laboratory and tailings impoundment facility is owned by China Minerals.
- Approximately 316,000 ounces of gold have been produced at the adjacent Table Mountain Mine from 1979-2007 under various companies.
- Current Resource Estimates for the Table Mountain Mine are 21,471 tonnes grading 18.02 g/t indicated and 65,757 tonnes grading 24.3 g/t inferred were reported at the adjacent property in the May, 2010 NI43-101 Technical Report on the Table Mountain Property by C. Pearson and F.J. Bakker.
- The Vines Lake Property is located approximately two kilometres southwest of the former Erickson gold mine.
- Two significant anomalies have been identified by geophysical surveys.
- The claims cover formations of the Sylvester group, which are known to contain productive zones of gold mineralization in the area.
- The Eastern side of the sample area hosts gold and silver soil anomalies
- The Western side of the sample area hosts zinc, barium and bismuth anomalies.
- Highway 37 N bisects the property north to south providing excellent year-round access.
On behalf of Lomiko Metals Inc,
A. Paul Gill, President & CEO
We seek safe harbor.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
647-607-6023
Bay Street Connect
info@lomiko.com
Lomiko Metals Inc.
www.lomiko.com
Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. Lomiko Metals Inc. (TSX-V: LMR) three month showcase gold stock on Investorideas.com and all related mining portals and blogs (one thousand per month)
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Biotech and Pharma News; Aethlon (OTCBB: AEMD) Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation
SAN DIEGO � October 5, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® and HER2osome™ cancer therapy will be the subject of a presentation at the Exosomes and Microvesicles 2011 conference on October 17th. The event is being held at the Wyndham Lake Buena Vista Resort located in Walt Disney World, Florida. Dr. Annette Marleau, Director of Tumor Immunology at Aethlon Medical will give the presentation. Both the Aethlon Hemopurifier® and HER2osome™ represent novel exosome-targeted strategies to improve cancer treatment outcomes. Exosomes released by cancers have recently emerged to become therapeutic targets in cancer care, as they are implicated in cancer survival, growth, and metastasis. Researchers have also identified that cancer-released exosomes assist tumors in evading the response of the immune system.
About HER2osome™
HER2osome™ provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein. HER2osome™ is a novel medical device, whose goal is to inhibit HER2+ breast cancer progression by reducing the circulatory presence of HER2 protein and tumor-secreted exosomes that contribute to the development and progression of breast cancer. Research publications indicate that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin® (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer. As an adjunct therapeutic candidate, HER2osome™ offers to fill an unmet medical need and enhance the benefit of Herceptin® and standard of care chemotherapies without adding drug toxicity or interaction risks.
About the Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and numerous bioterror and pandemic threats. Human studies have demonstrated the Hemopurifier® to be safe and provide average viral load reductions of greater than 50% during four-hour treatment periods in both HCV and HIV infected individuals without the administration of antiviral drugs. The device is currently the subject of a human clinical study in India to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy. An investigational device exemption (IDE) to initiate clinical studies in the United States is pending with The Food and Drug Administration (FDA).
In vitro studies have also documented that the Hemopurifier® captures exosomes underlying cancer, including colorectal, lymphoma, melanoma, ovarian, and breast cancer. Aethlon recently expanded its exosome research programs through a collaborative agreement with the Sarcoma Oncology Center (SOC), based in Santa Monica, California. The SOC collaboration is studying the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients. The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma.
To support the advancement of its therapeutic candidates, Aethlon has developed a diagnostic assay known as ELLSA™ that is able to identify and quantify the presence of exosomes in blood and other fluids. Aethlon plans to license or sell this technology to an organization already established in the research diagnostics field.
The Aethlon Hemopurifier® and HER2osome™ were both developed from the Aethlon ADAPT™ system, an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that selectively target the clearance of harmful agents from the entire circulatory system without the loss of essential blood components. Therapies that evolve from the Aethlon ADAPT™ system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technology as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies. Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT™ therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics. As Aethlon advances its current pipeline of therapies toward market, the company will market the ADAPT™ system to government agencies and organizations representing the pharmaceutical, biotechnology and medical device industry. On September 30, 2011, Aethlon was awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device from the ADAPT™ system that would reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
SAN DIEGO � October 5, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® and HER2osome™ cancer therapy will be the subject of a presentation at the Exosomes and Microvesicles 2011 conference on October 17th. The event is being held at the Wyndham Lake Buena Vista Resort located in Walt Disney World, Florida. Dr. Annette Marleau, Director of Tumor Immunology at Aethlon Medical will give the presentation. Both the Aethlon Hemopurifier® and HER2osome™ represent novel exosome-targeted strategies to improve cancer treatment outcomes. Exosomes released by cancers have recently emerged to become therapeutic targets in cancer care, as they are implicated in cancer survival, growth, and metastasis. Researchers have also identified that cancer-released exosomes assist tumors in evading the response of the immune system.
About HER2osome™
HER2osome™ provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein. HER2osome™ is a novel medical device, whose goal is to inhibit HER2+ breast cancer progression by reducing the circulatory presence of HER2 protein and tumor-secreted exosomes that contribute to the development and progression of breast cancer. Research publications indicate that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin® (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer. As an adjunct therapeutic candidate, HER2osome™ offers to fill an unmet medical need and enhance the benefit of Herceptin® and standard of care chemotherapies without adding drug toxicity or interaction risks.
About the Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and numerous bioterror and pandemic threats. Human studies have demonstrated the Hemopurifier® to be safe and provide average viral load reductions of greater than 50% during four-hour treatment periods in both HCV and HIV infected individuals without the administration of antiviral drugs. The device is currently the subject of a human clinical study in India to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy. An investigational device exemption (IDE) to initiate clinical studies in the United States is pending with The Food and Drug Administration (FDA).
In vitro studies have also documented that the Hemopurifier® captures exosomes underlying cancer, including colorectal, lymphoma, melanoma, ovarian, and breast cancer. Aethlon recently expanded its exosome research programs through a collaborative agreement with the Sarcoma Oncology Center (SOC), based in Santa Monica, California. The SOC collaboration is studying the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients. The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma.
To support the advancement of its therapeutic candidates, Aethlon has developed a diagnostic assay known as ELLSA™ that is able to identify and quantify the presence of exosomes in blood and other fluids. Aethlon plans to license or sell this technology to an organization already established in the research diagnostics field.
The Aethlon Hemopurifier® and HER2osome™ were both developed from the Aethlon ADAPT™ system, an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that selectively target the clearance of harmful agents from the entire circulatory system without the loss of essential blood components. Therapies that evolve from the Aethlon ADAPT™ system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technology as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies. Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT™ therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics. As Aethlon advances its current pipeline of therapies toward market, the company will market the ADAPT™ system to government agencies and organizations representing the pharmaceutical, biotechnology and medical device industry. On September 30, 2011, Aethlon was awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device from the ADAPT™ system that would reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page
Sorteo Games launches new traditional and web-based scratch games with the National Lottery of Mexico
SAN DIEGO and MEXICO CITY - October 5, 2011 (Investorideas.com Newswire) - Sorteo Games Inc., the leading provider of regulated server-based lottery systems in Latin America, today announced that its wholly-owned subsidiary, Digital Orchid Mexico, through its exclusive platform and distribution agreements with the National Lottery of Mexico, successfully launched 5 new traditional physical scratch games and a suite of over 40 innovative web-based instant and draw lottery games.
In a presentation to a large group representing all of the leading press and media agencies at the National Lottery headquarters in Mexico City, the General Director of the National Lottery, Benjamin Gonzalez Roaro, announced the launch of newly designed scratch games branded "RASCADITAS" in both the traditional scratch card format and e-versions. He also launched the new publicity campaign called "RASCA Y GANA" "SCRATCH AND WIN" with a National TV ad campaign featuring five amazing different puppies scratching enlarged versions of the five new scratch games and winning instantly.
"Our new National Lottery traditional scratch cards and our suite of over forty new innovative interactive instant and draw based games are being launched nationwide in Mexico through the exclusive Digital Orchid™ Distribution Platform. This is an integral part of our strategy to expand our core lottery business nationwide by attracting new players through both innovative and traditional exclusive regulated branded gaming products and services." said Mr. Jorge Gaviño, Marketing and Services General Sub Director of the National Lottery.
"The launch of the new National Lottery branded scratch & win cards now distributed in real time through our secure wireless agent terminals and the full suite of e-scratch and e-draw games offered on the official National Lottery website (juegaenlinea.lotenal.gob.mx) allows us to expand our leading regulated server-based lottery distribution systems to other leading regulated lotteries worldwide." said Nour-Dean Anakar, President and CEO of Sorteo Games and its fully owned subsidiary Digital Orchid Mexico.
Robert Betros, the COO of Sorteo Games Inc. in San Diego, explained that the e-scratch games were provided on the Digital Orchid™ Interactive Gaming Platform for the National Lottery of Mexico through an exclusive content development agreement with NeoGames, the global leader of online scratch and instant win games. This further enhances our platform by combining the security and convenience of playing our existing regulated branded national lottery draw games online, with the entertainment, branded content and immediate gratification of instant games.
Mexico's National Lottery, one of the leading lottery networks in all of the Americas, has deployed the Digital Orchid™ Interactive Gaming Platform for the distribution of their current pre-printed traditional lottery tickets and new scratch games as well as to provide a platform for expansion into new interactive games and electronic distribution channels. With this new capability, The National Lottery of Mexico has now officially launched the new popular scratch ticket sales through the Digital Orchid™ Wireless Handheld Agent Terminal Network that has been deployed to hundreds of National Lottery agents and street sellers nationwide.
The Sorteo Games Digital Orchid™ platform supports all on-line retail agent points of sales, reseller terminals, interactive kiosks, and direct to consumer web and mobile channels with sales for the full range of instant and draw games provided by the National Lottery of Mexico, such as the popular Sorteo Mayor weekly draw and the annual Gordo De Navidad Lotto. In addition, to the new instant scratch games and the 40+ interactive games, other popular progressive Lotto Jackpot Games will be launched in the near term.
The Digital Orchid™ platform supports services such as online player registrations, automated player notifications, player management and customer service functions, Pre-Paid Cards, real-time debit and credit card deposits, player e-wallets, and automatic payments directly to player bank accounts.
Throughout its 235-year history, revenues from Mexico's LoterÃa Nacional para la Asistencia Pública have contributed to the grandeur of Mexico. Its revenues have been employed for building bridges, highways and railroads nationwide, to promote culture and the arts and, above all, to support many significant social welfare programs in the areas of health and public education. Ever since the first drawing of Mexico's state-run lottery was held in 1771, millions of Mexicans have been passionate players of their National Lottery.
About Sorteo Games (www.sorteogames.com)
With offices in San Diego and Mexico City, Sorteo Games is a leading provider of regulated server-based wireless, Web and electronic lottery systems and services in Latin America. The Company's solutions enable lottery institutions and leading regulated gaming networks to more efficiently create, distribute and control traditional lottery products in conjunction with new electronic products, services and distribution channels.
www.sorteogames.com
juegaenlinea.lotenal.gob.mx/
Media Contact:
Robert Betros Sorteo Games Inc.
858-554-0297
Info@SorteoGames.com
SAN DIEGO and MEXICO CITY - October 5, 2011 (Investorideas.com Newswire) - Sorteo Games Inc., the leading provider of regulated server-based lottery systems in Latin America, today announced that its wholly-owned subsidiary, Digital Orchid Mexico, through its exclusive platform and distribution agreements with the National Lottery of Mexico, successfully launched 5 new traditional physical scratch games and a suite of over 40 innovative web-based instant and draw lottery games.
In a presentation to a large group representing all of the leading press and media agencies at the National Lottery headquarters in Mexico City, the General Director of the National Lottery, Benjamin Gonzalez Roaro, announced the launch of newly designed scratch games branded "RASCADITAS" in both the traditional scratch card format and e-versions. He also launched the new publicity campaign called "RASCA Y GANA" "SCRATCH AND WIN" with a National TV ad campaign featuring five amazing different puppies scratching enlarged versions of the five new scratch games and winning instantly.
"Our new National Lottery traditional scratch cards and our suite of over forty new innovative interactive instant and draw based games are being launched nationwide in Mexico through the exclusive Digital Orchid™ Distribution Platform. This is an integral part of our strategy to expand our core lottery business nationwide by attracting new players through both innovative and traditional exclusive regulated branded gaming products and services." said Mr. Jorge Gaviño, Marketing and Services General Sub Director of the National Lottery.
"The launch of the new National Lottery branded scratch & win cards now distributed in real time through our secure wireless agent terminals and the full suite of e-scratch and e-draw games offered on the official National Lottery website (juegaenlinea.lotenal.gob.mx) allows us to expand our leading regulated server-based lottery distribution systems to other leading regulated lotteries worldwide." said Nour-Dean Anakar, President and CEO of Sorteo Games and its fully owned subsidiary Digital Orchid Mexico.
Robert Betros, the COO of Sorteo Games Inc. in San Diego, explained that the e-scratch games were provided on the Digital Orchid™ Interactive Gaming Platform for the National Lottery of Mexico through an exclusive content development agreement with NeoGames, the global leader of online scratch and instant win games. This further enhances our platform by combining the security and convenience of playing our existing regulated branded national lottery draw games online, with the entertainment, branded content and immediate gratification of instant games.
Mexico's National Lottery, one of the leading lottery networks in all of the Americas, has deployed the Digital Orchid™ Interactive Gaming Platform for the distribution of their current pre-printed traditional lottery tickets and new scratch games as well as to provide a platform for expansion into new interactive games and electronic distribution channels. With this new capability, The National Lottery of Mexico has now officially launched the new popular scratch ticket sales through the Digital Orchid™ Wireless Handheld Agent Terminal Network that has been deployed to hundreds of National Lottery agents and street sellers nationwide.
The Sorteo Games Digital Orchid™ platform supports all on-line retail agent points of sales, reseller terminals, interactive kiosks, and direct to consumer web and mobile channels with sales for the full range of instant and draw games provided by the National Lottery of Mexico, such as the popular Sorteo Mayor weekly draw and the annual Gordo De Navidad Lotto. In addition, to the new instant scratch games and the 40+ interactive games, other popular progressive Lotto Jackpot Games will be launched in the near term.
The Digital Orchid™ platform supports services such as online player registrations, automated player notifications, player management and customer service functions, Pre-Paid Cards, real-time debit and credit card deposits, player e-wallets, and automatic payments directly to player bank accounts.
Throughout its 235-year history, revenues from Mexico's LoterÃa Nacional para la Asistencia Pública have contributed to the grandeur of Mexico. Its revenues have been employed for building bridges, highways and railroads nationwide, to promote culture and the arts and, above all, to support many significant social welfare programs in the areas of health and public education. Ever since the first drawing of Mexico's state-run lottery was held in 1771, millions of Mexicans have been passionate players of their National Lottery.
About Sorteo Games (www.sorteogames.com)
With offices in San Diego and Mexico City, Sorteo Games is a leading provider of regulated server-based wireless, Web and electronic lottery systems and services in Latin America. The Company's solutions enable lottery institutions and leading regulated gaming networks to more efficiently create, distribute and control traditional lottery products in conjunction with new electronic products, services and distribution channels.
www.sorteogames.com
juegaenlinea.lotenal.gob.mx/
Media Contact:
Robert Betros Sorteo Games Inc.
858-554-0297
Info@SorteoGames.com
New Direction Blowing in the Wind for Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Point Roberts WA - October 5, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, releases the following Q&A interview with Ron Pickett, President & CEO of Clean Wind Energy Tower, Inc. (OTCBB: CWET) following recent news from the Company on a change of business direction moving forward.
Q: Investorideas.com
Ron, in your recent press release you stated "the Company is transitioning from a "Research and Development Stage" company to the actual development of our first Dual Renewable Energy Tower project .” For new investors looking at the Company, can you explain the Downdraft tower and the new direction you are taking?
A: Ron Pickett, President & CEO
Our Downdraft Tower is simply a large hollow cylinder located in a very dry area like the Southwestern United States. We spray a fine mist of water near the top of the tower. The hot dry air absorbs the water, which becomes heavier, and sinks downward within the hollow cylinder creating a natural downdraft that is contained inside the tower. Turbines at the base of the tower power generators to make abundant electricity 24/7.
The next direction for the Company is to bring onboard an expert Development Team transitioning the Company from its research stage to actually developing the first Tower. That team will augment the development skills of existing management and combine them with the expertise of internationally recognized engineers, architects and contractors.
Q: Investorideas.com
Why hasn't this technology been deployed previously and how did a small Company like yours get access to it?
A: Ron Pickett, President & CEO
The technology or "technique” of creating a downdraft and containing it to harness wind energy was thoroughly studied by the Technion in Israel decades ago. The key to deployment rests with now proven construction techniques to erect the large tower combined with turbine and generator enhancements to extract maximum power from the downdraft.
Q: Investorideas.com
You also announced a change in share structure and a return to treasury of 120M plus shares . What does that mean to investors?
A: Ron Pickett, President & CEO
The Company recently announced that it had returned 120 million shares to treasury. This simply means that the total number of shares outstanding has been reduced from approximately 330M to 210M. That's about a 50% increase in value per share.
Q: Investorideas.com
What is the scope of a project like this in terms of feasibility, funding and then return on investment?
A: Ron Pickett, President & CEO
The financial feasibility of this project should be excellent. Our target is to present the first Tower project for financing with cash flow to support its debt with a 2:1 coverage. Unlike other "Green” Alternative Energy projects, which need subsidies and special financial incentives, our Tower is designed to be very profitable. The Dual Renewable Energy Tower is a totally "Green” project that generates a lot of "Green” profit.
Q: Investorideas.com
As investors have recently witnessed the failing of large scale solar companies like Solyndra that were funded by Government and investors – how do you differentiate a project on the scale you are undertaking and how are you sure it will succeed?
A: Ron Pickett, President & CEO
As stated above, traditional solar and wind projects need to be subsidized. Not so with our project. We will certainly seek to take advantage of any and all programs for tax-exempt bond financing and for tax and carbon credits. Nevertheless, we anticipate that our first project will be able to generate twice the cash flow before taxes necessary to service the required financing.
Wind Company Snapshot - Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc, is designing and preparing to develop, and construct large " Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies. In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity. Clean Wind has assembled a team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market. Clean Wind has filed several patents that the Company believes will further enhance this potentially revolutionary technology. www.cleanwindenergytower.com
Clean Wind Energy, Inc. Contact:
1997 Annapolis Exchange Parkway Suite 300
Annapolis , Maryland 21401
Phone: 410-972-4713
E-mail: Info@cwetower.com
Visit the CWET showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind and solar stocks
http://www.investorideas.com/Resources/Newsletter.asp
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Follow Investorideas.com on Twitterhttp://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebookhttp://www.facebook.com/Investorideas
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com contact:
800.665.0411
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
Point Roberts WA - October 5, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, releases the following Q&A interview with Ron Pickett, President & CEO of Clean Wind Energy Tower, Inc. (OTCBB: CWET) following recent news from the Company on a change of business direction moving forward.
Q: Investorideas.com
Ron, in your recent press release you stated "the Company is transitioning from a "Research and Development Stage" company to the actual development of our first Dual Renewable Energy Tower project .” For new investors looking at the Company, can you explain the Downdraft tower and the new direction you are taking?
A: Ron Pickett, President & CEO
Our Downdraft Tower is simply a large hollow cylinder located in a very dry area like the Southwestern United States. We spray a fine mist of water near the top of the tower. The hot dry air absorbs the water, which becomes heavier, and sinks downward within the hollow cylinder creating a natural downdraft that is contained inside the tower. Turbines at the base of the tower power generators to make abundant electricity 24/7.
The next direction for the Company is to bring onboard an expert Development Team transitioning the Company from its research stage to actually developing the first Tower. That team will augment the development skills of existing management and combine them with the expertise of internationally recognized engineers, architects and contractors.
Q: Investorideas.com
Why hasn't this technology been deployed previously and how did a small Company like yours get access to it?
A: Ron Pickett, President & CEO
The technology or "technique” of creating a downdraft and containing it to harness wind energy was thoroughly studied by the Technion in Israel decades ago. The key to deployment rests with now proven construction techniques to erect the large tower combined with turbine and generator enhancements to extract maximum power from the downdraft.
Q: Investorideas.com
You also announced a change in share structure and a return to treasury of 120M plus shares . What does that mean to investors?
A: Ron Pickett, President & CEO
The Company recently announced that it had returned 120 million shares to treasury. This simply means that the total number of shares outstanding has been reduced from approximately 330M to 210M. That's about a 50% increase in value per share.
Q: Investorideas.com
What is the scope of a project like this in terms of feasibility, funding and then return on investment?
A: Ron Pickett, President & CEO
The financial feasibility of this project should be excellent. Our target is to present the first Tower project for financing with cash flow to support its debt with a 2:1 coverage. Unlike other "Green” Alternative Energy projects, which need subsidies and special financial incentives, our Tower is designed to be very profitable. The Dual Renewable Energy Tower is a totally "Green” project that generates a lot of "Green” profit.
Q: Investorideas.com
As investors have recently witnessed the failing of large scale solar companies like Solyndra that were funded by Government and investors – how do you differentiate a project on the scale you are undertaking and how are you sure it will succeed?
A: Ron Pickett, President & CEO
As stated above, traditional solar and wind projects need to be subsidized. Not so with our project. We will certainly seek to take advantage of any and all programs for tax-exempt bond financing and for tax and carbon credits. Nevertheless, we anticipate that our first project will be able to generate twice the cash flow before taxes necessary to service the required financing.
Wind Company Snapshot - Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc, is designing and preparing to develop, and construct large " Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies. In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity. Clean Wind has assembled a team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market. Clean Wind has filed several patents that the Company believes will further enhance this potentially revolutionary technology. www.cleanwindenergytower.com
Clean Wind Energy, Inc. Contact:
1997 Annapolis Exchange Parkway Suite 300
Annapolis , Maryland 21401
Phone: 410-972-4713
E-mail: Info@cwetower.com
Visit the CWET showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind and solar stocks
http://www.investorideas.com/Resources/Newsletter.asp
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Follow Investorideas.com on Twitterhttp://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebookhttp://www.facebook.com/Investorideas
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com contact:
800.665.0411
Visit the CWET showcase page at Investorideas.com:
http://www.investorideas.com/CO/CWE/
http://www.investorideas.com/CO/CWE/
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com and our Green Investor content:http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asphttp://www.investorideas.com/Resources/Newsletter.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
Tuesday's Infrastructure Stocks Trading; (NYSE : BIP), (TSX: CSE), (OTCBB: FRCN), (TSX: ARF)
POINT ROBERTS - October 5, 2011 - www.InvestorIdeas.com, a leader in sector stock research including construction stocks, homebuilder and infrastructure stocks releases the following close-up on small and large cap infrastructure stocks for Tuesday October 4th and why one analyst likes the sector.
ARMTEC INFRASTRUCTURE INC. (Toronto: ARF.TO) closed up at $1.04, up 0.20 (23.81%) on 220,062 shares. The last news reported by the company
POINT ROBERTS - October 5, 2011 - www.InvestorIdeas.com, a leader in sector stock research including construction stocks, homebuilder and infrastructure stocks releases the following close-up on small and large cap infrastructure stocks for Tuesday October 4th and why one analyst likes the sector.
ARMTEC INFRASTRUCTURE INC. (Toronto: ARF.TO) closed up at $1.04, up 0.20 (23.81%) on 220,062 shares. The last news reported by the company was in August, that it had completed a refinancing of its existing senior bank facility. Pursuant to the refinancing, Armtec has borrowed $125 million under a senior secured loan facility with a Brookfield Asset Management Inc. company.
Recent commentary in the Globe and Mail quoted fund manager Oscar Belaiche as liking infrastructure stocks “because of their earnings stability from long-term contracts that can be indexed to inflation. He owns pipeline operators such as Enbridge Inc. and TransCanada Corp. as well as utilities such as Northland Power Inc., Innergex Renewable Energy Inc. and Brookfield Renewable Power Fund.”
Fireman's Contractors Inc. (OTCBB: FRCN) reported news Tuesday of a 390% increase in revenue for Fiscal 2011. The CEO of Fireman's Contractors, Renee Gilmore stated, "The past fiscal year was one of tremendous growth for Fireman's Contractors. We raised revenues by 390.59% while significantly expanding our customer base. We contribute our increase in revenues to hard work and dedication as we provided top quality workmanship to our clients. As we move forward in the development and explanation of our business, our goal is to continue building valuable relationships with our clients by providing a high level of professionalism."
The recently listed OTC stock has been trading with a range of $0.11-$0.16.
Capstone Infrastructure Corporation (TSX:CSE ; TSX:CSE.DB.A ; TSX:CSE.PR. A ; on Monday declared its first dividend on its Cumulative 5-Year Rate Reset Preferred Shares, Series A (the "Preferred Shares") of $0.4212 per Preferred Share to be paid on October 31, 2011 to shareholders of record at the close of trading on October 14, 2011. This initial dividend on the Preferred Shares covers the period from June 30, 2011 to October 31, 2011. Future dividends on the Preferred Shares are expected to be $0.3125 quarterly, or $1.25 per share on an annualized basis, for the initial five-year period, which ends on July 31, 2016. The stock closed at $5.88.
Brookfield Infrastructure (NYSE: BIP) (TSX: BIP.UN) closed at $23.00 on just over 1.2 million shares. According to commentary on Motley Fool on Monday its one of five star stocks poised to pop for investors.
Showcase Infrastructure Stock
Visit the company Profile on Investorideas.com
http://www.investorideas.com/CO/FRCN/
About Fireman's Contractors Inc. (OTCBB: FRCN)
Fireman's Contractors Inc. (OTCBB: FRCN) is a full service contractor providing superior service in parking lot maintenance and construction services. Our services include Road Improvements, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, ADA Compliance and other construction services which are delivered at a competitive price. Fireman's brings professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations. http://www.firemans-contractors.com/
Follow FIREMANS CONTRACTORS, Inc. (OTCBB: FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB: FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors
IR Contact info:
Tel: 1(214) 314-1588
Email: invest@firemanscontractors.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: Fireman's Contractors Inc. (OTCBB: FRCN) is a paid adverting construction stock on Investorideas.com and blogs (ten thousand for 3 months of advertising)
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411
POINT ROBERTS - October 5, 2011 - www.InvestorIdeas.com, a leader in sector stock research including construction stocks, homebuilder and infrastructure stocks releases the following close-up on small and large cap infrastructure stocks for Tuesday October 4th and why one analyst likes the sector.
ARMTEC INFRASTRUCTURE INC. (Toronto: ARF.TO) closed up at $1.04, up 0.20 (23.81%) on 220,062 shares. The last news reported by the company
POINT ROBERTS - October 5, 2011 - www.InvestorIdeas.com, a leader in sector stock research including construction stocks, homebuilder and infrastructure stocks releases the following close-up on small and large cap infrastructure stocks for Tuesday October 4th and why one analyst likes the sector.
ARMTEC INFRASTRUCTURE INC. (Toronto: ARF.TO) closed up at $1.04, up 0.20 (23.81%) on 220,062 shares. The last news reported by the company was in August, that it had completed a refinancing of its existing senior bank facility. Pursuant to the refinancing, Armtec has borrowed $125 million under a senior secured loan facility with a Brookfield Asset Management Inc. company.
Recent commentary in the Globe and Mail quoted fund manager Oscar Belaiche as liking infrastructure stocks “because of their earnings stability from long-term contracts that can be indexed to inflation. He owns pipeline operators such as Enbridge Inc. and TransCanada Corp. as well as utilities such as Northland Power Inc., Innergex Renewable Energy Inc. and Brookfield Renewable Power Fund.”
Fireman's Contractors Inc. (OTCBB: FRCN) reported news Tuesday of a 390% increase in revenue for Fiscal 2011. The CEO of Fireman's Contractors, Renee Gilmore stated, "The past fiscal year was one of tremendous growth for Fireman's Contractors. We raised revenues by 390.59% while significantly expanding our customer base. We contribute our increase in revenues to hard work and dedication as we provided top quality workmanship to our clients. As we move forward in the development and explanation of our business, our goal is to continue building valuable relationships with our clients by providing a high level of professionalism."
The recently listed OTC stock has been trading with a range of $0.11-$0.16.
Capstone Infrastructure Corporation (TSX:CSE ; TSX:CSE.DB.A ; TSX:CSE.PR. A ; on Monday declared its first dividend on its Cumulative 5-Year Rate Reset Preferred Shares, Series A (the "Preferred Shares") of $0.4212 per Preferred Share to be paid on October 31, 2011 to shareholders of record at the close of trading on October 14, 2011. This initial dividend on the Preferred Shares covers the period from June 30, 2011 to October 31, 2011. Future dividends on the Preferred Shares are expected to be $0.3125 quarterly, or $1.25 per share on an annualized basis, for the initial five-year period, which ends on July 31, 2016. The stock closed at $5.88.
Brookfield Infrastructure (NYSE: BIP) (TSX: BIP.UN) closed at $23.00 on just over 1.2 million shares. According to commentary on Motley Fool on Monday its one of five star stocks poised to pop for investors.
Showcase Infrastructure Stock
Visit the company Profile on Investorideas.com
http://www.investorideas.com/CO/FRCN/
About Fireman's Contractors Inc. (OTCBB: FRCN)
Fireman's Contractors Inc. (OTCBB: FRCN) is a full service contractor providing superior service in parking lot maintenance and construction services. Our services include Road Improvements, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, ADA Compliance and other construction services which are delivered at a competitive price. Fireman's brings professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations. http://www.firemans-contractors.com/
Follow FIREMANS CONTRACTORS, Inc. (OTCBB: FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB: FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors
IR Contact info:
Tel: 1(214) 314-1588
Email: invest@firemanscontractors.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: Fireman's Contractors Inc. (OTCBB: FRCN) is a paid adverting construction stock on Investorideas.com and blogs (ten thousand for 3 months of advertising)
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411
Tuesday, October 04, 2011
Infrastructure Stocks News; Fireman's Contractors (OTCBB:FRCN) Reports 390% Increase in Revenue for Fiscal 2011
FORT WORTH, Texas - October 4, 2011 (Investorideas.com Newswire) Fireman's Contractors Inc. (OTCBB:FRCN.OB) (OTCQB:FRCN.OB) is a full service contractor providing professional services for commercial and government clients in Asphalt Maintenance and Repair, Road Improvements, Seal Coating, Parking Lot Maintenance, and Pavement Marking reported a 390.59% for is Fiscal 2011 year ending June 30th, 2011.
Fiscal 2011 Financial Highlights:
Gross Revenue increased 390.59% in fiscal 2011, July 1st 2010 thru June 30th, 2011.
Key elements for gross revenue increase:
FIREMAN'S CONTRACTORS Inc. (OTCBB:FRCN.OB) is a full service contractor providing superior service in parking lot maintenance and construction services. Our services include Road Improvements, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, ADA Compliance and other construction services which are delivered at a competitive price. Fireman's brings professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations.
To learn more about Fireman's Contractors, please visit our website: http://www.Firemans-Contractors.com
Firefighter and Founder of Fireman's Contractors -- Contractors You Can Trust (R)
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. Additional information respecting the factors that could materially affect the Company and its operations are contained in its annual report on Form 10K and Form 10-Q as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement.
Contact:
FIREMAN'S CONTRACTORS Inc.
2406 Gravel Road
Fort Worth, TX 76118
Phone: 800-475-1479
info@FiremansContractors.com
Investor Relations Contact:
John Pentony, IR Affiliates
Contact: john@iraffiliates.com
Tel: 469.252.3031
Public Relations Contact:
Danielle O'Neal
Contact: PR@FiremansContractors.com
Tel: 800-475-1479
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors
FORT WORTH, Texas - October 4, 2011 (Investorideas.com Newswire) Fireman's Contractors Inc. (OTCBB:FRCN.OB) (OTCQB:FRCN.OB) is a full service contractor providing professional services for commercial and government clients in Asphalt Maintenance and Repair, Road Improvements, Seal Coating, Parking Lot Maintenance, and Pavement Marking reported a 390.59% for is Fiscal 2011 year ending June 30th, 2011.
Fiscal 2011 Financial Highlights:
Gross Revenue increased 390.59% in fiscal 2011, July 1st 2010 thru June 30th, 2011.
Key elements for gross revenue increase:
- Continuing efforts to cultivate relationships with commercial clients resulting in 30+% in repeat business
- Our effort in business development to focus on larger government and municipal opportunities
- The addition of our V.P. of Operations, Gary Cochran that helped streamlined productivity
- The addition of our V.P. of Business Development, Steve Winters which allowed the company to increase its business development team, training and take advantage of opportunities in the market
FIREMAN'S CONTRACTORS Inc. (OTCBB:FRCN.OB) is a full service contractor providing superior service in parking lot maintenance and construction services. Our services include Road Improvements, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, ADA Compliance and other construction services which are delivered at a competitive price. Fireman's brings professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations.
To learn more about Fireman's Contractors, please visit our website: http://www.Firemans-Contractors.com
Firefighter and Founder of Fireman's Contractors -- Contractors You Can Trust (R)
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. Additional information respecting the factors that could materially affect the Company and its operations are contained in its annual report on Form 10K and Form 10-Q as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement.
Contact:
FIREMAN'S CONTRACTORS Inc.
2406 Gravel Road
Fort Worth, TX 76118
Phone: 800-475-1479
info@FiremansContractors.com
Investor Relations Contact:
John Pentony, IR Affiliates
Contact: john@iraffiliates.com
Tel: 469.252.3031
Public Relations Contact:
Danielle O'Neal
Contact: PR@FiremansContractors.com
Tel: 800-475-1479
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors
Fireman's Contractors Inc. (OTCBB:FRCN), (OTCQB:FRCN.OB) is a featured construction stock on Investorideas.com
Visit the company profile to learn more: http://www.investorideas.com/CO/FRCN/
Disclaimer/ Disclosure: FRCN has compensated Investorideas.com ten thousand for three months of advertising. All info published is sourced from public files or the Company. This is not a solicitation go buy or sell securities.
Biotech/Pharma Investor Alert; BioSante (NASDAQ: BPAX) Trading up over 10% on News of Top LibiGel efficacy trial results
Point Roberts, WA; LINCOLNSHIRE, Ill - October 4, 2011 - Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/ pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), following news released from the Company October 4th.
The stock has bounced back as high as $2.25 in today's trading and is up 10.94% on news of completion of its two pivotal LibiGel (testosterone gel) efficacy trials.
According to reports on Seeking Alpha, "5 Stocks Trading Under $10 That Could Surge Higher", there is more upside for the stock.
News Excerpt: Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Completes Both Pivotal LibiGel® Efficacy Trials
"LINCOLNSHIRE, Ill. - October 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). The final visit of the last subject enrolled in the second of the two pivotal LibiGel Phase III efficacy trials occurred at the end of September. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
Data are being collected from the 141 investigative sites in the U.S. and Canada that participated in the two trials, and BioSante expects to announce top-line LibiGel efficacy results during this quarter. Both efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA). The third and last pivotal study for the LibiGel clinical development program is the ongoing LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of 3,656 subjects. The primary analysis of safety data is targeted for third quarter of 2012. The LibiGel NDA submission will include data from the two efficacy trials as well as the safety study and is targeted for the fourth quarter of 2012."
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/10041.asp
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com .
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact BioSante:
For info about BioSante Pharmaceuticals, Inc
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com
800 665 0411 cvanzant@investorideas.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
Point Roberts, WA; LINCOLNSHIRE, Ill - October 4, 2011 - Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/ pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), following news released from the Company October 4th.
The stock has bounced back as high as $2.25 in today's trading and is up 10.94% on news of completion of its two pivotal LibiGel (testosterone gel) efficacy trials.
According to reports on Seeking Alpha, "5 Stocks Trading Under $10 That Could Surge Higher", there is more upside for the stock.
News Excerpt: Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Completes Both Pivotal LibiGel® Efficacy Trials"LINCOLNSHIRE, Ill. - October 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). The final visit of the last subject enrolled in the second of the two pivotal LibiGel Phase III efficacy trials occurred at the end of September. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
Data are being collected from the 141 investigative sites in the U.S. and Canada that participated in the two trials, and BioSante expects to announce top-line LibiGel efficacy results during this quarter. Both efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA). The third and last pivotal study for the LibiGel clinical development program is the ongoing LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of 3,656 subjects. The primary analysis of safety data is targeted for third quarter of 2012. The LibiGel NDA submission will include data from the two efficacy trials as well as the safety study and is targeted for the fourth quarter of 2012."
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/10041.asp
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com .
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact BioSante:
For info about BioSante Pharmaceuticals, Inc
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com
800 665 0411 cvanzant@investorideas.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
Biotech and Pharma stocks News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Completes Both Pivotal LibiGel® Efficacy Trials
LINCOLNSHIRE, Ill. - October 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). The final visit of the last subject enrolled in the second of the two pivotal LibiGel Phase III efficacy trials occurred at the end of September. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
Data are being collected from the 141 investigative sites in the U.S. and Canada that participated in the two trials, and BioSante expects to announce top-line LibiGel efficacy results during this quarter. Both efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA). The third and last pivotal study for the LibiGel clinical development program is the ongoing LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of 3,656 subjects. The primary analysis of safety data is targeted for third quarter of 2012. The LibiGel NDA submission will include data from the two efficacy trials as well as the safety study and is targeted for the fourth quarter of 2012.
"We are delighted to have completed both LibiGel Phase III efficacy trials. We appreciate the diligence of the investigative sites and their care of the subjects in the trials, and we also thank the participating subjects," noted Joanne Zborowski, BioSante's vice president of clinical development. "There were over 1,100 subjects enrolled in the two efficacy trials, and we look forward to analyzing the data and announcing the results later this year."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The completed Phase III efficacy trials are double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from HSDD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the UnitedStates , in surgically menopausal women distressed by their low sexual desire and activity.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued over 4,800 women-years of exposure, to date. The study will continue for a total of five years; however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to demonstrate the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval of LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the fourth quarter of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to its future operations and products, the timing of anticipated clinical development milestones and regulatory submissions and other statements identified by words such as �anticipates,� �expects,� �will,� �continue,� �could,� �believes,� �intends,� �estimates,� �may,� other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
LINCOLNSHIRE, Ill. - October 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). The final visit of the last subject enrolled in the second of the two pivotal LibiGel Phase III efficacy trials occurred at the end of September. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
Data are being collected from the 141 investigative sites in the U.S. and Canada that participated in the two trials, and BioSante expects to announce top-line LibiGel efficacy results during this quarter. Both efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA). The third and last pivotal study for the LibiGel clinical development program is the ongoing LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of 3,656 subjects. The primary analysis of safety data is targeted for third quarter of 2012. The LibiGel NDA submission will include data from the two efficacy trials as well as the safety study and is targeted for the fourth quarter of 2012.
"We are delighted to have completed both LibiGel Phase III efficacy trials. We appreciate the diligence of the investigative sites and their care of the subjects in the trials, and we also thank the participating subjects," noted Joanne Zborowski, BioSante's vice president of clinical development. "There were over 1,100 subjects enrolled in the two efficacy trials, and we look forward to analyzing the data and announcing the results later this year."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The completed Phase III efficacy trials are double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from HSDD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued over 4,800 women-years of exposure, to date. The study will continue for a total of five years; however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to demonstrate the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval of LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the fourth quarter of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to its future operations and products, the timing of anticipated clinical development milestones and regulatory submissions and other statements identified by words such as �anticipates,� �expects,� �will,� �continue,� �could,� �believes,� �intends,� �estimates,� �may,� other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
Subscribe to:
Posts (Atom)